Michael Ryskin
BofA Securities, Research Division

Thanks for joining us for our next session. My name is Mike Ryskin. I'm on the Bank of America Life Science Tools and Diagnostics team, and we're excited to be hosting Qiagen. We're joined by Roland Sackers, Chief Financial Officer; and Domenica Martorana. Format will be a fireside chat Q&A as usual. Raise your hand if you've got any questions. Happy to let you jump in.

Michael Ryskin
BofA Securities, Research Division

Roland, had some updates yesterday from you in terms of the Board meeting updates, things like that. Anything specific you want to call out from there? We saw some changes to the Board, a little bit of an update on CEO timing. Just maybe you could talk through some of the key takes from that.

Roland Sackers
CFO, MD & Member of Management Board

Yes, sure. And first of all, thanks for having us. It's always a pleasure to be here. It's a long trip, but it's, for sure, worthwhile the trip. And again, thanks for having us. 2 days fully booked. But I do think what is important, and you will mention it, that yesterday, we released the proxy for the upcoming AGM. I do think it has a couple of exciting news.

And I think let's start with getting certain things out of our way. Probably very important is we are asking for approval of more share buybacks. As you know, Qiagen has this, I would say, setting that we do, 2 different kinds of share